Romidepsin
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Explore 59 assets in Primary Cutaneous T-Cell Non-Hodgkin Lymphoma →Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Walter Hanel
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04774068CT.gov Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas | — | Completed | — | — | — |
NCT04447027CT.gov Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies | — | Completed | — | — | — |
NCT03432741CT.gov Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | — | Terminated | — | — | — |
NCT02512497CT.gov Romidepsin Maintenance After Allogeneic Stem Cell Transplantation | — | Completed | — | — | — |
NCT03278782CT.gov Study of Pembrolizumab (MK-3475) in Combination With Romidepsin | — | Active Not Recruiting | — | — | — |
NCT02616965CT.gov A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma | — | Completed | — | — | — |
NCT02757248CT.gov Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL | — | Withdrawn | — | — | — |
NCT02232516CT.gov Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | — | Completed | — | — | — |
NCT02181218CT.gov Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas | — | Completed | — | — | — |
NCT02296398CT.gov Long-term Use of Romidepsin in Patients With CTCL | — | Completed | — | — | — |
Show 6 more trialsShow fewer
NCT02061449CT.gov Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma | — | Terminated | — | — | — |
NCT01738594CT.gov Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma | — | Terminated | — | — | — |
NCT01638533CT.gov Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | — | Completed | — | — | — |
NCT01445340CT.gov Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma | — | Terminated | — | — | — |
NCT00106431CT.gov A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) | — | Completed | — | — | — |
NCT00007345CT.gov Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Romidepsin (this asset) | Walter Hanel | P2 | BB · 68 |
| (+)-Vincristine | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Cyclophosphamide | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Dexasone | National Cancer Institute (NCI) | P2 | BBB |
| Bexarotene | Case Comprehensive Cancer Center | P4 | BBB |
| Nivestim | City of Hope Medical Center | P4 | BBB |
| Fludarabine | National Cancer Institute (NCI) | P2 | BBB |
| Adriamycin | Falo, Louis, MD | P4 | BBB |
| Etoposide | City of Hope Medical Center | P2 | BB |
+42 more in the Primary Cutaneous T-Cell Non-Hodgkin Lymphoma cohort
Other indications for Romidepsin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Burkitt Lymphoma | — | P2 | BBB · 73 |
| Follicular Lymphoma | — | P2 | BBB · 73 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Romidepsin in Primary Cutaneous T-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/romidepsin-primary-cutaneous-t-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →